Replies to post #94162 on Biotech Values

[masterlongevity]

campath:

their claim may end up being true, but this is a very agressive move for a product to claim based on ph 2 results. For the sake of MS patients, I hope they are right.

I think the gilenia data look stellar, although efficacy may not be as high as tysabri or what was reported by campath. all three are in the same ballpark.